STOCK TITAN
  1. Home
  2. News
  3. ANGO

Angiodynamic Inc - ANGO STOCK NEWS

Welcome to our dedicated news page for Angiodynamic (Ticker: ANGO), a resource for investors and traders seeking the latest updates and insights on Angiodynamic.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Angiodynamic's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Angiodynamic's position in the market.

News
AngioDynamics Reports Fiscal Year 2024 Third Quarter Financial Results; Updates Fiscal Year 2024 Guidance to Reflect Asset Divestiture
Rhea-AI Summary
AngioDynamics, Inc. (NASDAQ: ANGO) announced its Fiscal Year 2024 Third Quarter Highlights, including the sale of PICC and Midline product portfolios, discontinuation of certain products, and financial results. Net sales were $66.0 million, with a 8.0% growth. Gross margin was 47.7%, GAAP loss per share was $(4.73), and adjusted loss per share was $(0.16). The Company recorded a GAAP net loss of $190.4 million. Med Tech net sales increased by 12.6% to $25.7 million, while Med Device net sales increased by 5.2% to $40.3 million. The Company's financial guidance for fiscal year 2024 includes net sales in the range of $270 to $275 million, gross margin of 52.0% to 54.0%, and adjusted loss per share of $0.54 to $0.58.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.26%
Tags
earnings
-
News
AngioDynamics Receives 510(k) Clearance for AlphaVac F18⁸⁵ System in Treatment of PE
Rhea-AI Summary
AngioDynamics, Inc. announces FDA clearance for AlphaVac F1885 System for the treatment of pulmonary embolism, enhancing patient care and safety. The system broadens treatment options, reduces thrombus burden, and improves right ventricular function. APEX-AV study results show significant reduction in RV/LV ratio and clot burden, with low MAEs rate.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.26%
Tags
none
-
News
AngioDynamics Announces Settlement of All Patent Litigation with C.R. Bard, Inc.
Rhea-AI Summary
AngioDynamics, Inc. (ANGO) has settled all outstanding patent litigation with Becton, Dickinson and Company (BD) through a settlement agreement, involving licensing agreements and a $7 million lump sum payment. The agreement includes annual payments to BD and potential additional payments based on net sales. The settlement resolves a multi-year patent dispute, providing clarity and allowing AngioDynamics to focus on innovation and growth.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.17%
Tags
none
News
AngioDynamics to Report Fiscal 2024 Third Quarter Financial Results on April 4, 2024
Rhea-AI Summary
AngioDynamics, Inc. (ANGO) will report Q3 fiscal year 2024 financial results on April 4, 2024, followed by a conference call. Investors can access the call via phone or webcast on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.72%
Tags
conferences earnings
-
News
AngioDynamics to Participate in a Fireside Chat at the Oppenheimer Virtual Healthcare MedTech & Services Conference
Rhea-AI Summary
AngioDynamics, Inc. (ANGO) announced participation in Oppenheimer conference for discussing healthcare and medtech innovations. The company aims to enhance blood flow, cancer treatments, and patient well-being.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.23%
Tags
conferences
-
News
AngioDynamics Announces Sale of PICC and Midline Product Portfolios to Spectrum Vascular for $45 Million
Rhea-AI Summary
AngioDynamics, Inc. (ANGO) completes the sale of its PICC and Midline product portfolios to Spectrum Vascular for up to $45 million in cash. The company discontinues sales of radiofrequency ablation and Syntrax products to streamline its portfolio. The divestiture and discontinuation are part of the company's strategic focus on driving growth and profitability within its Med Tech platforms.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.32%
Tags
none
News
AngioDynamics Announces FDA 510(k) Clearance of Auryon XL Radial Access Catheter to Treat Peripheral Arterial Disease
Rhea-AI Summary
AngioDynamics, Inc. (ANGO) has received FDA clearance for the Auryon XL Catheter, expanding access points in atherectomy procedures for the treatment of Peripheral Arterial Disease (PAD). The catheter's innovative design aims to reduce access site complications and accelerate patient recovery. The company anticipates a full market release in February 2024 after a limited market release in January 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.66%
Tags
clinical trial
-
News
AngioDynamics Reports Fiscal Year 2024 Second Quarter Financial Results; Revises Fiscal Year 2024 Guidance
Rhea-AI Summary
AngioDynamics, Inc. (NASDAQ: ANGO) announced net sales of $79.1 million for the second quarter of fiscal year 2024, with a 2.7% increase on a pro-forma basis compared to the prior-year quarter. The company reported a GAAP loss per share of $0.72 and adjusted loss per share of $0.05. Cash and cash equivalents at November 30, 2023, were $60.9 million. The company expects to achieve full-year adjusted EPS profitability in FY27.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-19.87%
Tags
earnings
-
News
AngioDynamics to Present at the J.P. Morgan Healthcare Conference
Rhea-AI Summary
AngioDynamics, Inc. (NASDAQ: ANGO) announced that its President and CEO, Jim Clemmer, and EVP and CFO, Stephen Trowbridge, will present at the J.P. Morgan 42nd Annual Healthcare Conference on January 11, 2024. The presentation will focus on the company's medical technology innovations and cancer treatment advancements.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.45%
Tags
conferences
News
AngioDynamics to Report Fiscal 2024 Second Quarter Financial Results on January 5, 2024
Rhea-AI Summary
AngioDynamics, Inc. (NASDAQ: ANGO) will report financial results for Q2 of fiscal year 2024 on January 5, 2024. The management will host a conference call to discuss the results, accessible via phone or webcast. The webcast replay and call recording will also be available for a limited time.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1%
Tags
conferences earnings
Stock ANGO logo
Angiodynamic Inc

Nasdaq:ANGO

ANGO Rankings

#3636 Ranked by Market Cap
#4793 Ranked by Stock Gains
N/A Ranked by Dividends

ANGO Stock Data

260.75M
38.86M
5%
91.34%
5.65%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
US
Latham

About ANGO

founded in 1988 in queensbury, n.y., u.s., angiodynamics is today a nasdaq-listed public company. we are a leading provider of innovative medical devices used by interventional radiologists, nephrologists and surgeons for the minimally invasive treatment of cancer and peripheral vascular disease. our diverse product line includes market-leading radiofrequency ablation and nanoknife® systems, vascular access products, angiographic products and accessories, dialysis products, angioplasty products, drainage products, thrombolytic products, embolization products and venous products. angiodynamics has distinguished itself as a dynamic brand in a technologically competitive, high-growth industry, through the company’s consistent ability to successfully develop and bring to market new technologies and products. angiodynamics believes it is well poised to continue that trend. looking into the future, the company plans to bring forth a continuing stream of innovations that greatly improve patie